Diagnosis and Therapy for Patients with Philadelphia positive chronic myeloid leukemia - Guidelines of Croatian cooperative group for hematologic disorders (Krohem)
作者： Rajko Kušec , Velka Gverić-Krečak , Ljubica Škare-Librenjak , Antica Duletić-Načinović , Jasminka Petričević-Sinčić
DOI:
关键词:
摘要: Prijedlog Hrvatske kooperativne grupe za hematoloske bolesti (Krohem) smjernica dijagnostickog i terapijskog pristupa Philadelphia pozitivnu kronicnu mijeloicnu leukemiju. Metode: Dijagnoza KML-a temelji se na kriterijima dijagnostike podjele mijeloidnih zlocudnih tumora Svjetske zdravstvene organizacije (SZO). Razina terapijskih preporuka polazi od pokazatelja koje predlaže elektronicki izvor medicinskih informacija UpToDate®. Rezultati: Za dijagnozu potrebno je dokazati prisustvo kromosoma tehnikama klasicne citogenetike ili BCR-ABL prijepis FISH-om molekularnim tehnikama. Lijecenje primjeni inhibitora tirozin kinaze. Dasatinib nilotinib pokazuju bolji antileukemijski ucinak imatiniba. Zbog raspoloživosti lijekova u Hrvatskoj, ovom trenutku imatinib dalje primjenjuje prvoj liniji terapije. U bolesnika s nepovoljnim odgovorom, ovisno o prethodnom lijecenju, drugoj primjenjuju bilo dasatinib nilotinib. uznapredovanoj fazi bolesti, ubrzanoj blasticnoj krizi, terapija izbora alogena transplantacija. Prije transplantacije lijecenje inhibitorima kinaze, kako bi smanjila leukemijska masa bolesti. Bolesnici mutacijom abl proteina T315I otporni su kinaze zahtijevaju sto moguce brže alogenom transplantacijom. Rasprava zakljucak: Terapija Ph+ KML-u kronicnoj inhibitori optimalnim terapijskim odgovorom postiže dugotrajna kontrola dobra kvaliteta života. mutacije T315I,
参考文章(57)
P. C. Nowell, A minute chromosome in human chronic granulocytic leukemia Science. ,vol. 132, pp. 1497- ,(1960)
Dan Jones, Suzanne Kamel-Reid, David Bahler, Henry Dong, Kojo Elenitoba-Johnson, Richard Press, Neil Quigley, Paul Rothberg, Dan Sabath, David Viswanatha, Karen Weck, James Zehnder, Laboratory Practice Guidelines for Detecting and Reporting BCR-ABL Drug Resistance Mutations in Chronic Myelogenous Leukemia and Acute Lymphoblastic Leukemia The Journal of Molecular Diagnostics. ,vol. 11, pp. 4- 11 ,(2009) , 10.2353/JMOLDX.2009.080095
David A. Irvine, Nicholas B. Heaney, Tessa L. Holyoake, Optimising chronic myeloid leukaemia therapy in the face of resistance to tyrosine kinase inhibitors--a synthesis of clinical and laboratory data. Blood Reviews. ,vol. 24, pp. 1- 9 ,(2010) , 10.1016/J.BLRE.2009.11.002
J DEGROOT, B ZONNENBERG, J PLUKKER, W VANDERGRAAF, T LINKS, Imatinib induces hypothyroidism in patients receiving levothyroxine. Clinical Pharmacology & Therapeutics. ,vol. 78, pp. 433- 438 ,(2005) , 10.1016/J.CLPT.2005.06.010
Aine Carol Burke, Ronan T Swords, Kevin Kelly, Francis J Giles, Current status of agents active against the T315I chronic myeloid leukemia phenotype Expert Opinion on Emerging Drugs. ,vol. 16, pp. 85- 103 ,(2011) , 10.1517/14728214.2011.531698
Donna L. Forrest, Shannon Trainor, Ryan R. Brinkman, Michael J. Barnett, Donna E. Hogge, Thomas J. Nevill, John D. Shepherd, Stephen H. Nantel, Cynthia L. Toze, Heather J. Sutherland, Kevin W. Song, Julye C. Lavoie, Maryse M. Power, Yasser Abou-Mourad, Clayton A. Smith, Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels Leukemia Research. ,vol. 33, pp. 271- 275 ,(2009) , 10.1016/J.LEUKRES.2008.07.015
Éva Oläh, Attila Kiss, János Jakq, Chromosome abnormalities, clinical and morphological manifestations in metamorphosis of chronic myeloid leukemia. International Journal of Cancer. ,vol. 26, pp. 37- 45 ,(1980) , 10.1002/IJC.2910260107
Timothy P. Hughes, Susan Branford, Measuring minimal residual disease in chronic myeloid leukemia: fluorescence in situ hybridization and polymerase chain reaction. Clinical Lymphoma, Myeloma & Leukemia. ,vol. 9, ,(2009) , 10.3816/CLM.2009.S.022
Massimo Breccia, Giuliana Alimena, Nilotinib and dasatinib first-line: are we ready for imatinib replacement? Leukemia Research. ,vol. 35, pp. 1153- 1155 ,(2011) , 10.1016/J.LEUKRES.2011.02.004
Francis J Giles, Gianantonio Rosti, Photis Beris, Richard E Clark, Philipp le Coutre, Francois-Xavier Mahon, Juan-Luis Steegmann, Peter Valent, Giuseppe Saglio, Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: the ENESTnd study. Expert Review of Hematology. ,vol. 3, pp. 665- 673 ,(2010) , 10.1586/EHM.10.61